In August 2025, the European Commission formally approved the twice-yearly injection for HIV prevention developed by Gilead Sciences, making it available for countries in the EU. Since the jab was authorised in the US earlier in June, experts and activists have called on Gilead to make the drug more accessible. Marketed as Yeztugo by pharmaceutical…
